{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-22-000113","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.132610+00:00","generated_at":"2026-06-22T17:29:43.729478+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AtriCure Q3 revenue $83.2M (+18.1% YoY); net loss $0.27/share; guides FY2022 rev ~$328-333M","bullets":["Revenue $83.2M, up 18.1% YoY (19.8% constant currency). US revenue $69.8M (+21.3%).","Gross margin flat at 74.1%; operating loss $10.7M vs income $98.7M in Q3 2021 (includes non-recurring items).","Adjusted EBITDA negative $0.7M vs positive $0.7M last year; adjusted EPS loss $0.27 vs $0.23.","FY 2022 guidance: revenue ~$328-333M (20-21% growth), adjusted EBITDA loss ~$4M, adjusted loss per share ~$1.10-$1.12.","Growth driven by cryoSPHERE pain management, AtriClip Flex·V, and EnCompass clamp; international growth in Australia and Japan."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-22-000113","json":"https://secwatch.observer/filing/0001323885-22-000113.json","markdown":"https://secwatch.observer/filing/0001323885-22-000113.md","text":"https://secwatch.observer/filing/0001323885-22-000113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000113/0001323885-22-000113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000113/atrc-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T17:29:43.729478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"515445e1b1698c650a609b610784cd4708c905e8","claim":"AtriCure, Inc. reported the third quarter ended September 30, 2022 results: revenue $83.2 million, EPS $0.27.","evidence_excerpt":"Revenue for the third quarter 2022 was $83.2 million, an increase of 18.1% (an increase of 19.8% on a constant currency basis) over third quarter 2021 revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000113/0001323885-22-000113-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$83.2 million"},{"label":"EPS","value":"$0.27"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}